GW-842,166X

GW-842,166X
Identifiers
	IUPAC name 2-(2,4-dichloroanilino)-N-(tetrahydropyran-4-ylmethyl)-4-(trifluoromethyl)pyrimidine-5-carboxamide;
CAS Number	666260-75-9;
PubChem CID	10253143;
ChemSpider	8428629;
UNII	VL1I6P2DZ8;
ChEMBL	ChEMBL225411;
CompTox Dashboard (EPA)	DTXSID60216786 ;
Chemical and physical data
Formula	C18H17Cl2F3N4O2
Molar mass	449.26 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C3COCCC3CNC(=O)c1cnc(nc1C(F)(F)F)Nc2ccc(Cl)cc2Cl;
	InChI InChI=1S/C18H17Cl2F3N4O2/c19-11-1-2-14(13(20)7-11)26-17-25-9-12(15(27-17)18(21,22)23)16(28)24-8-10-3-5-29-6-4-10/h1-2,7,9-10H,3-6,8H2,(H,24,28)(H,25,26,27); Key:TWQYWUXBZHPIIV-UHFFFAOYSA-N;
	(verify)

GW-842,166X is a drug which acts as a potent and selective cannabinoid CB₂ receptor agonist, with a novel chemical structure based on a pyrimidine core. It has potent analgesic, anti-inflammatory and anti-hyperalgesic actions in animal models, but without cannabis-like behavioural effects due to its extremely low affinity for the CB₁ receptor.^[1]^[2] GSK brought this compound for into 4 clinical trials, two of them related to pain management^[3]^[4] and the other two related to bio-distributions.^[5]^[6] The trials were either withdrawn or completed without posting result.

References

^ Giblin GM, O'Shaughnessy CT, Naylor A, Mitchell WL, Eatherton AJ, Slingsby BP, et al. (May 2007). "Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain". Journal of Medicinal Chemistry. 50 (11): 2597–2600. doi:10.1021/jm061195+. PMID 17477516.
^ Han S, Thatte J, Jones RM (2009). Chapter 11: Recent Advances in the Discovery of CB2 Selective Agonists. Annual Reports in Medicinal Chemistry. Vol. 44. pp. 227–246. doi:10.1016/S0065-7743(09)04411-X. ISBN 9780123747662.
^ "Dose Response and Efficacy of GW842166 in Pain - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. 12 February 2015. Retrieved 2020-02-18.
^ "Dental Pain 3rd Molar Tooth Extraction GW842166 - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. 15 May 2009. Retrieved 2020-02-18.
^ "Relative Bioavailability Study on a Single Dose of GW842166X in Healthy Male and Female Subjects. - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. 12 February 2015. Retrieved 2020-02-18.
^ "An Imaging Study to Investigate the Distribution of GW842166X in the Brain. - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. 3 August 2017. Retrieved 2020-02-18.

GW-842,166X

References

Suggest as cover photo

Thank you for helping!

Install Wikiwand

Don't forget to rate us

Tell your friends about Wikiwand!

Enjoying Wikiwand?

Tell your friends and spread the love:

Your preferred languages

All languages

Follow Us

Don't forget to rate us

Our magic isn't perfect

Thank you for helping!

Oh no, there's been an error

Identifiers

IUPAC name 2-(2,4-dichloroanilino)-N-(tetrahydropyran-4-ylmethyl)-4-(trifluoromethyl)pyrimidine-5-carboxamide
CAS Number	666260-75-9
PubChem CID	10253143
ChemSpider	8428629
UNII	VL1I6P2DZ8
ChEMBL	ChEMBL225411
CompTox Dashboard (EPA)	DTXSID60216786
Chemical and physical data
Formula	C₁₈H₁₇Cl₂F₃N₄O₂
Molar mass	449.26 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES C3COCCC3CNC(=O)c1cnc(nc1C(F)(F)F)Nc2ccc(Cl)cc2Cl
InChI InChI=1S/C18H17Cl2F3N4O2/c19-11-1-2-14(13(20)7-11)26-17-25-9-12(15(27-17)18(21,22)23)16(28)24-8-10-3-5-29-6-4-10/h1-2,7,9-10H,3-6,8H2,(H,24,28)(H,25,26,27) Key:TWQYWUXBZHPIIV-UHFFFAOYSA-N
(verify)